Core Insights - ProMIS Neurosciences Inc. is set to present preclinical data on computationally-derived vaccines targeting neurodegenerative diseases at the AAN Annual Meeting in April 2025 [1][2] Group 1: Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing antibody therapeutics and vaccines for neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) [9] - The company utilizes a proprietary computational discovery platform, ProMIS™, to identify Disease Specific Epitopes on misfolded proteins [9] - PMN310, the lead product candidate, is a humanized monoclonal antibody designed to selectively bind toxic soluble amyloid-beta oligomers, which are believed to be a primary cause of neurodegeneration in AD [7][8] Group 2: Research and Development - The preclinical studies demonstrated that immunization with a single conformational epitope, peptide 301, resulted in maximal reactivity against AD brain oligomers [4] - The company is exploring a novel approach to vaccine design that targets misfolded toxic proteins, aiming to induce a specific immune response against amyloid-beta oligomers for AD and pathogenic alpha-synuclein for MSA [2][5] - Results indicated that vaccination with conformational B cell epitopes produced high-affinity antibodies with selectivity for pathogenic alpha-synuclein, preserving normal protein function [6] Group 3: Upcoming Presentations - ProMIS Neurosciences will present two key studies at the AAN Annual Meeting: - The first study focuses on optimizing Alzheimer's vaccine configuration to target toxic amyloid-beta oligomers, presented by Dr. Johanne Kaplan on April 9, 2025 [3] - The second study discusses the rational design of a vaccine for synucleinopathies, presented by Dr. Johanne Kaplan on April 8, 2025 [5]